Neuroimaging Core

神经影像核心

• 批准号: 10663897
• 负责人: JOHN A DETRE
• 金额: $ 67.59万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663897
• 关键词: Aging; Alzheimer disease detection; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Amyloid; Amyloid beta-Protein; Angiography; Autopsy; Biological; Biological Markers; Blood Vessels; Brain; Brain imaging; Cerebral hemisphere; Clinical; Clinical Research; Collaborations; Consensus; Data; Data Provenance; Databases; Development; Dimensions; Disease; Disease Progression; Doctor of Medicine; Doctor of Philosophy; Evaluation; Functional Imaging; Genetic; Genomics; Heterogeneity; Histopathology; Image; Image Analysis; Incidence; Infrastructure; Institution; Intervention; Link; MRI Scans; Magnetic Resonance Imaging; Maps; Measures; Metadata; Methods; Modality; Molecular; Monitor; Nerve Degeneration; Neurodegenerative Disorders; Optical Coherence Tomography; Participant; Pathology; Phenotype; Plasma; Positron-Emission Tomography; Procedures; Process; Protocols documentation; Reproducibility; Research; Research Personnel; Research Subjects; Resources; Retina; Risk; Sampling; Scanning; Scientist; Slide; Specificity; Staging; Structure; Tissues; Tracer; Training and Education; Translations; Universities; Update; Validation; Washington; biomarker development; brain behavior; brain tissue; clinical center; cohort; data infrastructure; data integration; data management; data sharing; digital; digital pathology; education research; flexibility; image guided; imaging informatics; imaging study; in vivo; informatics infrastructure; insight; ischemic lesion; method development; molecular imaging; morphometry; multimodality; neuroimaging; neuroimaging marker; neuroinflammation; neuropathology; neurovascular; novel; outreach; perfusion imaging; pre-clinical; radioligand; recruit; retinal imaging; statistics; structural imaging; tau Proteins

Neuroimaging Core Project Summary Because of their tolerability, versatility, and spatial specificity, neuroimaging biomarkers are a prominent strategy used in AD/ADRD research to detect AD pathology, provide insights into disease mechanism and heterogeneity, track disease progression and, ultimately, monitor the efficacy of disease-modifying interventions. Neuroimaging methods can also noninvasively assess other neuropathophysiological mechanisms such as neurovascular insufficiency and neuroinflammation that are implicated as mechanisms and modulators of AD and therefore likely contribute to the heterogeneity observed in its risk, incidence, and progression. When linked to postmortem measures of proteinopathy burden, imaging measures can shed light on heterogeneity of AD/ADRD, allowing for discovery of in vivo signatures of “pure AD” and concomitant non- AD pathologies. The Penn ADRC Neuroimaging Core will consolidate expertise in advanced neuroimaging methods and applications to support the acquisition and analysis of state-of-the-art multimodal MRI of brain structure and function, molecular brain imaging using PET, retinal angiography using optical coherence tomography (OCTA). The Neuroimaging Core will oversee the acquisition and analysis of standard MRI and PET scans used in defining preclinical AD based on amyloid, tau, and neurodegeneration (“A/T/(N)”) staging and for quantifying ischemic lesions in the brain. Additional unique features of the Neuroimaging Core include the use of ultra- high-field (7T) MRI both in vivo and for post-mortem imaging of intact hemispheres, the development methods for accurate image-guided sampling of post-mortem brain tissue allowing spatial linkage between digital pathology and in vivo morphometry, the development a data infrastructure linking imaging and non-imaging databases, novel MRI and OCT methods for quantifying brain structure and vascular function in ADRC research, and infrastructure to support the translation of novel PET tracers to clinical research in AD/ADRD. The Neuroimaging Core will also share imaging data collected at the Penn ADRC with the NACC Coordinating Center at the University of Washington and SCAN U24. The Neuroimaging Core will be highly integrated with other ADRC cores, providing access to advanced imaging and derived imaging metrics for the Clinical Core, collaboration on image analysis and databasing of image-based information with the Data Management and Statistics Core, linking in vivo and postmortem neuroimaging to neuropathology in conjunction with the Neuropathology Core, leveraging imaging as a means of linking genetic factors with structural and functional brain phenotype with Genomics Core, working with the Outreach Recruitment and Engagement Core to provide research updates about neuroimaging advances and promote participation in imaging studies, and providing education and training in neuroimaging through Research Education Component.

神经影像核心项目总结 由于其耐受性、多功能性和空间特异性，神经影像学生物标志物是一种突出的 AD/ADRD研究中使用的策略，以检测AD病理，提供对疾病机制的见解， 异质性，跟踪疾病进展，并最终监测疾病改善的疗效。 干预措施。神经影像学方法也可以无创地评估其他神经病理生理学 神经血管功能不全和神经炎症等机制， 和AD的调节剂，因此可能有助于在其风险、发病率和 进展当与蛋白质病负担的死后测量相联系时，成像测量可以揭示 在AD/ADRD的异质性上，允许发现“纯AD”和伴随的非- AD病理学。 宾夕法尼亚州ADRC神经影像核心将巩固先进的神经影像方法的专业知识， 应用程序，以支持采集和分析最先进的多模态MRI的大脑结构和 功能，使用PET的分子脑成像，使用光学相干断层扫描（OCTA）的视网膜血管造影。 神经影像学核心将监督标准MRI和PET扫描的采集和分析， 基于淀粉样蛋白、tau和神经变性（“A/T/（N）”）分期定义临床前AD，并用于定量 脑缺血性损伤Neuroimaging Core的其他独特功能包括使用超 高场（7 T）MRI在体内和死后成像的完整半球，开发方法 用于死后脑组织的精确图像引导采样， 病理学和体内形态测量学，开发连接成像和非成像的数据基础设施 数据库，用于量化ADRC中脑结构和血管功能的新型MRI和OCT方法 研究和基础设施，以支持新的PET示踪剂在AD/ADRD的临床研究的翻译。 神经影像学核心还将与NACC协调中心共享在Penn ADRC收集的成像数据。 中心在华盛顿大学和扫描U24。 神经成像核心将与其他ADRC核心高度集成，提供先进的 临床核心的成像和衍生成像指标，图像分析和数据库方面的合作， 基于图像的信息与数据管理和统计核心，连接在体内和死后 神经影像学与神经病理学结合神经病理学核心，利用影像学作为一种手段 将遗传因素与结构和功能性大脑表型联系起来， 外展招募和参与核心，提供有关神经影像学进展的最新研究， 促进参与成像研究，并通过以下方式提供神经成像方面的教育和培训： 研究教育部分。